Merck Wins Defense Verdict In 2nd N.J. Fosamax Jaw Injury Trial

Merck Wins Defense Verdict In 2nd N.J. Fosamax Jaw Injury Trial

ATLANTIC CITY, N.J. - A New Jersey state court jury on April 18 found that the osteoporosis drug Fosamax did not cause a plaintiff's osteonecrosis of the jaw (ONJ) (Jo Ann Sessner v. Merck, Sharpe & Dohme, Inc., No. ATL-L-3394-11-MT, N.J. Super., Atlantic Co.). Subscribers may view the verdict available within the full update.

Find full version on lexis Advance®
Access this news story on lexis.com®